AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
Fierce Biotech1d
AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
Business Matters4d
Astrazeneca scrapped £450m vaccine plant after government missed funding deadline
AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The ...
Fierce Pharma1d
Fierce Pharma Asia—AstraZeneca-Alteogen drug delivery deal; Taiho's ADC buyout; WuXi's rosy 2025 outlook
AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...
China Daily1d
AstraZeneca to establish a new global strategic R&D center in Beijing
AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth ...
Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Therapeutic Antibodies
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
Medical Marketing & Media3d
AstraZeneca takes to the pickleball court for Fasenra campaign
AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma treatment Fasenra.
Clinical Trials Arena on MSN4d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
AstraZeneca acquired the hypoparathyroidism therapy eneboparatide as part of a buyout of Amolyt Pharma in July 2024.